Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04860297
Recruitment Status : Recruiting
First Posted : April 26, 2021
Last Update Posted : March 25, 2022
Sponsor:
Information provided by (Responsible Party):
ModernaTX, Inc.

Brief Summary:
This is an open-label study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1273 Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) vaccine in adults with a kidney or liver solid organ transplant (SOT) and in healthy adult participants. The primary goal of the study is to evaluate the safety of mRNA-1273 and the serum antibody (Ab) responses obtained 28 days after the last dose of mRNA-1273.

Condition or disease Intervention/treatment Phase
SARS-CoV-2 Biological: mRNA-1273 Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: This is an open-label, single intervention study; there is no randomization
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS-CoV-2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls
Actual Study Start Date : April 16, 2021
Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : January 31, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: mRNA-1273

Part A: All participants (healthy participants and SOT participants) who were unvaccinated prior to enrollment will receive 2 intramuscular (IM) injections of 100 microgram (µg) mRNA-1273 on Day 1 and Day 29.

All SOT participants who were unvaccinated prior to enrollment will be offered the opportunity to receive a third primary dose of mRNA-1273 at Day 85 as per the emergency use authorization (EUA) Fact Sheet available at the time of protocol finalization.

SOT participants who were previously vaccinated with 2 doses of Moderna COVID-19 vaccine under the EUA prior to enrollment will receive Dose 3 on Day 1.

Part B: All eligible participants from Part A will be offered to receive a 100 µg booster dose of mRNA-1273 who are at least 4 months from the last dose. SOT recipients who completed primary COVID-19 vaccination series with a non-Moderna COVID-19 under EUA (outside of the mRNA-1273-P304 study) will receive a 100 µg booster dose on booster dose Day 1.

Biological: mRNA-1273
Sterile liquid for injection




Primary Outcome Measures :
  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) in Part A [ Time Frame: Up to Day 92 ]
  2. Number of Participants with Solicited Local and Systemic ARs in Part B [ Time Frame: Day 8 ]
  3. Number of Participants with Unsolicited Adverse Events (AEs) in Part A [ Time Frame: Up to Day 113 ]
  4. Number of Participants with Unsolicited AEs in Part B [ Time Frame: Day 29 ]
  5. Number of Participants with Medically-Attended AEs (MAAEs) [ Time Frame: up to approximately 1 year ]
  6. Number of Participants with Serious AEs (SAEs) [ Time Frame: up to approximately 1 year ]
  7. Number of Participants with AEs of Special Interest (AESIs) [ Time Frame: up to approximately 1 year ]
  8. Number of Participants with AEs Leading to Withdrawal [ Time Frame: up to approximately 1 year ]
  9. Number of Participants with Biopsy-Proven Organ Rejection [ Time Frame: up to approximately 1 year ]
  10. Geometric Mean Titer (GMT) of SARS-CoV-2 Specific Neutralizing Antibody (nAb) for Participants in Part A [ Time Frame: 28 days after last dose (Day 57 for unvaccinated participants who received 2 doses, Day 113 for unvaccinated SOT participants who received 3 doses, and Day 29 for previously vaccinated SOT participants) ]
  11. GMT of SARS-CoV-2 Specific nAB for Participants in Part B [ Time Frame: 28 days after booster dose (booster dose Day 29) ]

Secondary Outcome Measures :
  1. Geometric Mean (GM) of SARS-CoV-2 Binding Antibody (bAb) for Unvaccinated Participants Receiving 2-Dose Regimen [ Time Frame: Day 1, 29, 57, 209, and 394 ]
  2. GM of SARS-CoV-2 bAb for Unvaccinated SOT Participants Receiving 3-Dose Regimen [ Time Frame: Day 1, 29, 57, 85, 113, 265, and 450 ]
  3. GM of SARS-CoV-2 bAb for Previously Vaccinated SOT Participants [ Time Frame: Day 1, 29, 180, and 365 ]
  4. Geometric Mean Fold Rise (GMFR) of bAb Relative to Day 1 for Unvaccinated Participants Receiving 2-Dose Regimen [ Time Frame: Day 29, 57, 209, and 394 ]
  5. GMFR of bAb Relative to Day 1 for Unvaccinated SOT Participants Receiving 3-Dose Regimen [ Time Frame: Day 29, 57, 85, 113, 265, and 450 ]
  6. GMFR of bAb Relative to Day 1 for Previously Vaccinated SOT Participants [ Time Frame: Day 29, 180, and 365 ]
  7. The GMT Values of SARS-CoV-2-Specific nAb for Unvaccinated Participants Receiving 2-Dose Regimen [ Time Frame: Day 1, 29, 209, and 394 ]
  8. The GMT Values of SARS-CoV-2-Specific nAb for Unvaccinated SOT Participants Receiving 3-Dose Regimen [ Time Frame: Day 1, 29, 85, 113, 265, and 450 ]
  9. The GMT Values of SARS-CoV-2-Specific nAb for Previously Vaccinated SOT Participants [ Time Frame: Day 1, 29, 180, and 365 ]
  10. GMFR of nAb Relative to Day 1 For Unvaccinated Participants Receiving 2-Dose Regimen [ Time Frame: Day 29, 57, 209, and 394 ]
  11. GMFR of nAb Relative to Day 1 for Unvaccinated SOT Participants Receiving 3-Dose Regimen [ Time Frame: Day 29, 57, 85, 113, 265, and 450 ]
  12. GMFR of nAb Relative to Day 1 for Previously Vaccinated SOT Participants [ Time Frame: Day 29, 180, and 365 ]
  13. Number of Transplant Recipients and Number of Healthy Participants (Who had a Negative SARS-CoV-2 at Baseline) with Asymptomatic SARS-CoV-2 Infection [ Time Frame: Day 43 up to Day 394 for unvaccinated participants who received 2 doses, Day 99 up to Day 450 for unvaccinated SOT participants who received 3 doses, and Day 15 up to Day 365 for previously vaccinated SOT recipients ]
    Clinical signs indicative of asymptomatic SARS-CoV-2 infection as predefined for the study.

  14. Number of Transplant Recipients and Number of Healthy Participants with a First Occurrence of Symptomatic COVID-19 Starting 14 Days after the Second Dose of Vaccine and after the Third Dose of Vaccine [ Time Frame: Day 43 up to Day 394 for unvaccinated participants who received 2 doses, Day 99 up to Day 450 for unvaccinated SOT participants who received 3 doses, and Day 15 up to Day 365 for previously vaccinated SOT recipients ]
    Clinical signs indicative of symptomatic COVID-19 as predefined for the study.

  15. Number of Transplant Recipients and Number of Healthy Participants with a First Occurrence of Severe COVID-19 Starting 14 Days after Second Dose of Vaccine and after the Third Dose of Vaccine [ Time Frame: Day 43 up to Day 394 for unvaccinated participants who received 2 doses, Day 99 up to Day 450 for unvaccinated SOT participants who received 3 doses, and Day 15 up to Day 365 for previously vaccinated SOT recipients ]
    Clinical signs indicative of severe COVID-19 as predefined for the study.

  16. Number of Participants with a Change in Immunosuppressant Medications to Treat Organ Transplant Rejection or to Improve Immune Tolerance [ Time Frame: Up to Day 394 for unvaccinated participants who received 2 doses, Up to Day 450 for unvaccinated SOT participants who received 3 doses, Up to Day 365 for previously vaccinated SOT recipients ]
    Change in immunosuppressant medication is defined as any of the following: -any adjustments (temporarily or permanently) in immunosuppressants; -addition of new immunosuppressants; -or switching from one maintenance rejection prophylaxis regimen to another



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Transplant Recipients

Key Inclusion Criteria for Part A:

  • Is either a kidney or a liver transplant recipient who is at least 90 days after transplantation at the time of consent, and is either unvaccinated or previously vaccinated with 2 doses of Moderna COVID-19 vaccine who is at least 1 month after the second dose at the time of consent. Participants who received the 2 doses of Moderna COVID-19 vaccine before transplant are not eligible.
  • Understands, agrees, and is able to comply with the study procedures and provides written informed consent.
  • Received chronic immunosuppressive therapy for the prevention of allograft rejection for a minimum of 90 days before signing consent, including but not limited to: glucocorticoids (such as, prednisolone), immunophilin binding agents (such as, calcineurin inhibitors, mTOR inhibitors), or inhibitors of de novo nucleotide synthesis (such as, mycophenolic acid, mizoribine, leflunomide, azathioprine).
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, agreement to continue adequate contraception or abstinence through 3 months following the second dose (Day 29) for those receiving 2-dose regimen and, through 3 months following the third dose (Day 85) for those receiving 3-dose regimen, and through 3 months following the third dose (Day 1) for those previously vaccinated SOT participants, and not currently breastfeeding.
  • Is medically stable, according to investigator's judgment, during the 3 months before signing consent.

Key Exclusion Criteria for Part A:

  • Has prior or planned administration of a coronavirus vaccine (for example, SARS-CoV-2 [for unvaccinated participants only], SARS-CoV, or MERS [Middle East Respiratory Syndrome] -CoV vaccine).
  • Has current treatment with investigational agents for either prophylaxis against COVID-19 (for unvaccinated participants only) or treatment of COVID-19 (such as, anti-SARS-CoV-2 monoclonal antibodies).
  • A history of more than one solid organ transplanted (such as, kidney and pancreas). A history of previous kidney or liver transplant is acceptable.
  • Has received therapies that have depleting properties on T cells, B cells, and plasma cells (examples of depletional therapies include, but are not limited to, antithymocyte globulin [ATG], monoclonal antibodies, and proteosome inhibitors) within the last 3 months prior to enrollment.
  • A history of biopsy-proven T-cell- or Ab-mediated rejection within 3 months of informed consent, or suspected active or chronic rejection according to the investigator's judgment.
  • Has a known close contact with anyone with laboratory confirmed SARS-CoV-2 infection within 2 weeks to vaccine administration or known history of SARS-CoV-2 infection or positive SARS-CoV-2 test.
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  • Has a history of clinically relevant donor-specific Ab.
  • Has a history of complications of immunosuppression
  • Suspected clinically relevant active hepatitis, including viral hepatitis, according to the investigator's judgment
  • Known human immunodeficiency virus (HIV) infection
  • Has a history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
  • Received any non-study vaccine within 28 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine)
  • Received intravenous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to Day 1.
  • Participated in an interventional clinical study within 28 days prior to Day 0 or plans to donate blood products while participating in this study.

Healthy Participants

Key Inclusion Criteria for Part A:

  • In good general health without current or previous diagnosis of immunocompromising condition, immune-mediated disease, or other immunosuppressive condition, according to investigator assessment, at the time of consent, and has not been vaccinated with any COVID-19 vaccine at the time of consent.
  • Understands, agrees, and is able to comply with the study procedures and provides written informed consent.
  • For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection (Day 1), agreement to continue adequate contraception or abstinence through 3 months following the second injection (Day 29), and not currently breastfeeding.
  • Is medically stable, according to investigator's judgment, during the 3 months before signing consent.

Key Exclusion Criteria for Part A:

  • Has a known close contact with anyone with laboratory confirmed SARS-CoV-2 infection or COVID-19 within 2 weeks prior to vaccine administration or known history of SARS-CoV-2 infection or positive SARS-CoV-2 test.
  • Has prior or planned administration of a coronavirus vaccine (for example, SARS-CoV-2, SARS-CoV, or MERS-CoV vaccine).
  • Has current treatment with investigational agents for either prophylaxis against COVID-19 or treatment of COVID-19 (for example, anti-SARS-CoV-2 monoclonal antibodies).
  • Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
  • Has a history of a diagnosis or condition that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety.
  • Received any non-study vaccine within 28 days before or after any dose of vaccine (except for seasonal influenza vaccine, which is not permitted within 14 days before or after any dose of vaccine)
  • Received intravenous blood products (red blood cells, platelets, immunoglobulins) within 3 months prior to Day 1.
  • Received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids ≥20 mg/day of prednisone equivalent).
  • Participated in an interventional clinical study within 28 days prior to Day 0 or plans to donate blood products while participating in this study.

Inclusion Criteria for Part B:

  • Participants must have been previously enrolled in this study (mRNA-1273-P304), are actively participating in Part A, and at least 4 months from the last dose; or participant is either a kidney or a liver SOT recipient who is at least 90 days after transplantation at the time of consent and who completed primary vaccination series (3 doses for mRNA COVID-19 vaccine; 2 doses for non-mRNA COVID-19 vaccine or at least 1 dose of non-mRNA combined with 1 dose of mRNA COVID-19 vaccine) under the EUA who are at least 4 months from the last dose. All primary COVID-19 vaccination series must be completed after transplant.
  • Female participants of childbearing potential may be enrolled in the study if the participant has a negative pregnancy test on the day of the first injection (booster dose Day 1).

Exclusion Criteria for Part B:

  • Exclusion Criteria in Part A will apply except prior or planned administration of a coronavirus vaccine and current treatment with investigational agents for either prophylaxis against COVID-19.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04860297


Contacts
Layout table for location contacts
Contact: Moderna Clinical Trials Support Center 1-877-777-7187 clinicaltrials@modernatx.com

Locations
Layout table for location information
United States, Georgia
Piedmont Transplant Institute Recruiting
Atlanta, Georgia, United States, 30309
United States, Washington
University of Washington Medical Center Not yet recruiting
Seattle, Washington, United States, 98195
Sponsors and Collaborators
ModernaTX, Inc.
Layout table for additonal information
Responsible Party: ModernaTX, Inc.
ClinicalTrials.gov Identifier: NCT04860297    
Other Study ID Numbers: mRNA-1273-P304
First Posted: April 26, 2021    Key Record Dates
Last Update Posted: March 25, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ModernaTX, Inc.:
mRNA-1273
mRNA-1273 vaccine
SARS-CoV-2
SARS-CoV-2 Vaccine
Coronavirus
Virus Diseases
Messenger RNA
COVID-19
COVID-19 Vaccine
Moderna
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases